Healthcare entity

Respiratory Syncytial Virus (RSV) vaccine

Product

market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention COVID-19 Vaccine, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Respiratory Syncytial Virus (RSV) vaccine, all published on July 21, 2026.

Last mentioned: Jul 21, 2026

RSS updates
Share

Entity pulse

Recent coverage · Respiratory Syncytial Virus (RSV) vaccine

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Respiratory Syncytial Virus (RSV) vaccine

market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention COVID-19 Vaccine, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Respiratory Syncytial Virus (RSV) vaccine, all published on July 21, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Respiratory Syncytial Virus (RSV) vaccine. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Cramer Endorsement & 109% YTD Gain

    Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.

  2. Quarterly Update

    Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.

  3. Post-Pandemic Decline

    Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.

  4. COVID Vaccine Success

    Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

Stories mentioning Respiratory Syncytial Virus (RSV) vaccine 1

Respiratory Syncytial Virus (RSV) vaccine is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.